



**Statement of stand-alone Financial Results for the quarter and year ended 31<sup>st</sup> March, 2013**

Rs. lakhs

PARTICULARS	THREE MONTHS ENDED (UN-AUDITED)			YEAR ENDED (AUDITED)	
	31-MAR-2013	31-DEC-2012	31-MAR-2012	31-MAR-2013	31-MAR-2012
<b>PART I : STATEMENT OF STAND-ALONE RESULTS</b>					
01. Gross Sales / Income from Operations	13536	13788	11839	54656	44150
Less : Excise Duty	435	508	179	2122	1347
Less : Sales Tax	278	229	313	1101	1119
Net Sales / Income from Operations	12823	13051	11347	51433	41684
02. Other Operating Income	1508	1980	1225	4492	1895
03. TOTAL INCOME FROM OPERATIONS	14331	15031	12572	55925	43579
04. EXPENDITURE					
a) Cost of materials consumed	4774	5064	3413	18063	11768
b) Purchases of stock-in-trade	70	55	330	558	1553
c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-690	-527	-42	-2125	75
d) Employee benefits expense	2087	1878	1814	8536	6713
e) Depreciation and amortization expense	536	550	378	1984	1541
f) Other Expenses	4688	3822	4085	15201	12322
TOTAL EXPENSES	11465	10842	9978	42217	33972
05. Profit / (Loss) from Operations before other income, finance costs and exceptional items	2866	4189	2594	13708	9607
06. Other Income	203	570	74	1194	940
07. Finance costs	769	731	609	2512	2296
08. Exceptional Items	-	541	-	1158	-
09. Profit / (Loss) from ordinary activities before tax	2300	3487	2059	11232	8251
10. Tax expense, including deferred tax	1128	1050	606	3419	2038
11. Net Profit / Loss (-) from ordinary activities after tax	1172	2437	1453	7813	6213
12. Paid-up Equity Share Capital (each share of Rs. 10/- face value)	3137	3137	3115	3137	3115
13. Reserves excluding revaluation reserves as per Balance Sheet of previous accounting year				50621	43632
14. Earnings per share – Basic and diluted EPS before and after extraordinary item (Rs.) – non-annualized	3.74 3.74	7.79 7.79	5.00 5.00	25.02 24.91	21.39 21.39
15. Public Shareholding:					
a) Number of Shares	13,594,593	13,603,193	13,378,081	13,594,593	13,378,081
b) Percentage of Shareholding	43.33	43.36	42.95	43.33	42.95
16. Promoters and Promoter Group Shareholding					
a) Pledged / Encumbered –	-	-	-	-	-
b) Non – encumbered – No. of shares	17,778,481	17,769,881	17,769,881	17,778,481	17,769,881
Percentage (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00
Percentage (as a % of the total share capital of the company)	56.67	56.64	57.05	56.67	57.05

Dated at Hyderabad, this, the 30<sup>th</sup> day of May, 2013.  
for and on behalf of the Board of Directors,  
**NATCO** Pharma Limited

  
V.C. Nannapaneni  
Chairman & Managing Director

Status of Investor Complaints as at 31<sup>st</sup> March, 2013

Pending as on 01-01-2013	Nil
Received during the quarter	57
Resolved during the quarter	57
Pending as on 31-03-2013	Nil



Statement of stand-alone Assets and Liabilities (Rs. in lakhs)

Particulars	As at 31-Mar-2013	As at 31-Mar-2012
<b>Equity &amp; Liabilities</b>		
<b>Shareholders' Funds</b>		
a) Share Capital	3137	3115
b) Reserves & Surplus	50621	43632
<b>Sub-total : Shareholders' funds</b>	<b>53758</b>	<b>46747</b>
<b>Non-current liabilities</b>		
a) Long term borrowings	13713	13410
b) Deferred tax liabilities (net)	4112	2889
c) Other long-term liabilities	69	135
d) Long term provisions	821	659
<b>Sub-total : Non-current Liabilities</b>	<b>18715</b>	<b>17093</b>
<b>Current Liabilities</b>		
a) Short term borrowings	14774	8164
b) Trade payables	10443	8387
c) Other current liabilities	8025	8184
d) Short-term provisions	33	342
<b>Sub-total : Current Liabilities</b>	<b>33275</b>	<b>25077</b>
<b>TOTAL – EQUITY AND LIABILITIES</b>	<b>105748</b>	<b>88917</b>
<b>Assets</b>		
<b>Non-current Assets</b>		
a) Fixed Assets		
- Tangible Assets	46565	30003
- Intangible Assets	491	178
b) Capital work-in-progress	7837	16443
c) Non-current investments	7753	7416
d) Long term loans and advances	12066	7578
e) Other non-current assets	13	42
<b>Sub-total : Non-current Assets</b>	<b>74725</b>	<b>61660</b>
<b>Current Assets</b>		
a) Current Investments	81	74
b) Inventories	12832	9728
c) Trade receivables	12646	9334
d) Cash and cash equivalents	937	3370
e) Short term loans and advances	4192	4264
f) Other current assets	335	487
<b>Sub-total : Current Assets</b>	<b>31023</b>	<b>27257</b>
<b>TOTAL – ASSETS</b>	<b>105748</b>	<b>88917</b>



**Statement of consolidated Financial Results for the quarter and year ended 31<sup>st</sup> March, 2013**

Rs. lakhs

PARTICULARS	THREE MONTHS ENDED (UNREVIEWED/UNAUDITED)			YEAR ENDED (AUDITED)	
	31-MAR-2013	31-DEC-2012	31-MAR-2012	31-MAR-2013	31-MAR-2012
<b>PART I : STATEMENT OF CONSOLIDATED RESULTS</b>					
01. Gross Sales / Income from Operations	16156	16515	14166	65302	52953
Less : Excise Duty	430	508	179	2122	1347
Less : Sales Tax	278	229	313	1101	1119
Net Sales / Income from Operations	15448	15778	13674	62079	50487
02. Other Operating Income	1283	1983	1218	4322	2605
03. TOTAL INCOME FROM OPERATIONS	16731	17761	14892	66401	53092
04. EXPENDITURE					
a) Cost of materials consumed	4794	5094	3413	17757	11767
b) Purchases of stock-in-trade	1586	2114	2289	8714	8682
c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-755	-527	-42	-2191	-161
d) Employee benefits expense	2539	2447	2176	10229	7777
e) Depreciation and amortization expense	625	634	166	2212	1583
f) Other Expenses	5143	4109	4473	16900	13478
TOTAL EXPENSES	13932	13871	12475	53621	43126
05. Profit / (Loss) from Operations before other income, finance costs and exceptional items	2799	3890	2417	12780	9966
06. Other Income	186	593	74	1241	350
07. Finance costs	823	758	621	2631	2362
08. Exceptional Item	-	541	-	1158	-
09. Profit / (Loss) from ordinary activities before tax	2162	3184	1870	10232	7954
10. Tax expense, including deferred tax	1321	1061	619	3644	2107
11. Minority Interest	-291	-136	-14	-599	-114
12. Net Profit / Loss (-) from ordinary activities after tax	1132	2259	1265	7187	5961
13. Paid-up Equity Share Capital (each share of Rs. 10/- face value)	3137	3137	3115	3137	3115
14. Reserves excluding revaluation reserves as per Balance Sheet of previous accounting year				50217	44249
<b>PART II : SELECT INFORMATION</b>					
15. Earnings per share – Basic and diluted EPS before and after extraordinary item (Rs.) – non-annualized	3.61 3.61	7.20 7.20	4.35 4.35	23.01 22.91	20.53 20.53
16. Public Shareholding:					
a) Number of Shares	13,594,593	13,603,193	13,378,081	13,594,593	13,378,081
b) Percentage of Shareholding	43.33	43.36	42.95	43.33	42.95
16. Promoters and Promoter Group Shareholding					
a) Pledged / Encumbered – No. of shares	-	-	-	-	-
b) Non – encumbered – No. of shares	17,778,481	17,769,881	17,769,881	17,778,481	17,769,881
Percentage (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00
Percentage (as a % of the total share capital of the company)	56.67	56.64	57.05	56.67	57.05

The above financial results were audited by the Statutory Auditors of the Company, the Audit Committee, and approved by the Board of Directors at a meeting held at Hyderabad, on Thursday, the 6<sup>th</sup> June, 2013. In respect of reference relating to non-accounting of minimum alternate tax credit, in the auditors' report, the company will review and evaluate the position during the current financial year and with respect to unaudited subsidiaries considered for consolidation, the management estimates that there is no significant impact of the same on reported profits. Figures for the previous period(s) have been re-arranged / re-grouped wherever necessary. Figures for the quarter ended on 31<sup>st</sup> March are the balancing figures between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the financial year. Exceptional item represents amount written off against a pending legal dispute. The stand-alone results are available on the company's web-site [www.natcopharma.co.in](http://www.natcopharma.co.in).

Dated at Hyderabad, this, the 6<sup>th</sup> June, 2013.  
for and on behalf of the Board of Directors,  
**NATCO Pharma Limited**

V.C. Nannapaneni  
Chairman & Managing Director

Status of Investor Complaints as at 31<sup>st</sup> March, 2013

Pending as on 01-01-2013	Nil
Received during the quarter	57
Resolved during the quarter	57
Pending as on 31-03-2013	Nil



Statement of Consolidated Assets and Liabilities (Rs. in lakhs)

Particulars	As at 31-Mar-2013	As at 31-Mar-2012
<b>Equity &amp; Liabilities</b>		
<b>Shareholders' Funds</b>		
a) Share Capital	3137	3115
b) Reserves & Surplus	50217	44249
<b>Sub-total : Shareholders' funds</b>	<b>53354</b>	<b>47364</b>
c) Minority Interest	1054	88
<b>Non-current liabilities</b>		
a) Long term borrowings	13783	13410
b) Deferred tax liabilities (net)	4432	2930
c) Other long-term liabilities	69	135
d) Long term provisions	862	659
<b>Sub-total : Non-current Liabilities</b>	<b>19146</b>	<b>17134</b>
<b>Current Liabilities</b>		
a) Short term borrowings	14774	8164
b) Trade payables	11430	9236
c) Other current liabilities	8177	8191
d) Short-term provisions	107	344
<b>Sub-total : Current Liabilities</b>	<b>34488</b>	<b>25935</b>
<b>TOTAL – EQUITY AND LIABILITIES</b>	<b>108042</b>	<b>90521</b>
<b>Assets</b>		
<b>Non-current Assets</b>		
a) Fixed Assets		
- Tangible Assets	55390	30091
- Intangible Assets	2884	1865
b) Capital work-in-progress	10584	16443
c) Non-current investments	154	6179
d) Long term loans and advances	5720	6622
e) Other non-current assets	13	42
<b>Sub-total : Non-current Assets</b>	<b>74745</b>	<b>61242</b>
<b>Current Assets</b>		
a) Current Investments	81	74
b) Inventories	14603	11039
c) Trade receivables	12971	9469
d) Cash and cash equivalents	1265	3663
e) Short term loans and advances	4041	4650
f) Other current assets	336	384
<b>Sub-total : Current Assets</b>	<b>33297</b>	<b>29279</b>
<b>TOTAL – ASSETS</b>	<b>108042</b>	<b>90521</b>



**Report of segment wise revenue, Results and Capital Employed, (Un-audited) under Clause 41 of the Listing Agreement, for the quarter and year ended on 31<sup>st</sup> March, 2013**

*Rs. lakhs*

	THREE MONTHS ENDED			YEAR ENDED	
	31-MAR-2013	31-DEC-2012	31-MAR-2012	31-MAR-2013	31-MAR-2012
<b>01. Segment Revenue (Net)</b>					
a) Bulk Chemicals	6562	6743	3421	23692	15662
b) Formulations	7572	6982	8485	29367	27126
c) Job Work	219	255	205	944	896
d) Unallocated	254	1391	682	3244	1416
<b>Total</b>	<b>14607</b>	<b>15371</b>	<b>12793</b>	<b>57247</b>	<b>45100</b>
Less : Inter-segment Revenue	276	340	221	1322	1521
<b>Net Sales / Income from Operations</b>	<b>14331</b>	<b>15031</b>	<b>12572</b>	<b>55925</b>	<b>43579</b>
<b>02. Segment Results : Profit (+)/Loss (-) before tax and interest</b>					
a) Bulk Chemicals	1541	1614	741	5527	2943
b) Formulations	3136	2531	1805	12235	9688
c) Job Work	129	208	169	728	727
d) Unallocated	223	1253	607	2915	1235
<b>Total</b>	<b>5029</b>	<b>5606</b>	<b>3322</b>	<b>21405</b>	<b>14593</b>
Less : a) Interest	770	731	609	2512	2296
b) Other unallocable expenditure	2162	1958	728	8855	4986
c) Unallocable income	(203)	(570)	-74	(1194)	(940)
<b>Total Profit Before Tax</b>	<b>2300</b>	<b>3487</b>	<b>2059</b>	<b>11232</b>	<b>8251</b>
<b>03. Capital Employed (Segment Assets - Segment Liabilities)</b>					
a) Bulk Chemicals	36375	37939	32093	36375	32093
b) Formulations	32742	31251	28721	32742	28721
c) Job Work	94	48	178	94	178
e) Unallocated (Others)	-15453	-16688	-14246	-15453	-14246
<b>Total</b>	<b>53758</b>	<b>52550</b>	<b>46746</b>	<b>53758</b>	<b>46746</b>

The above financial results were reviewed / audited by the Statutory Auditors of the Company, the Audit Committee, and approved by the Board of Directors at a meeting held at Hyderabad, on Thursday, the 30<sup>th</sup> May, 2013. In respect of reference relating to non-accounting of minimum alternate tax credit, in the auditors' report, the company will review and evaluate the position during the current financial year. Figures for the previous period(s) have been re-arranged / re-grouped wherever necessary. Figures for the quarter ended on 31<sup>st</sup> March are the balancing figures between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the financial year. Exceptional item represents amount written off against a pending legal dispute. The stand-alone results are available on the company's web-site [www.natcopharma.co.in](http://www.natcopharma.co.in).

Dated at Hyderabad, this, the 30<sup>th</sup> day of May, 2013.

for and on behalf of the Board of Directors,

**NATCO** Pharma Limited

V.C. Nannapaneni  
Chairman & Managing Director

Regd. Office: **NATCO** House, Road # 2, Banjara Hills, **Hyderabad : 500 033.**